“Eltrombopag for the treatment of thrombocytopenia due to low-and intermediate risk myelodyysplastic syndromes”. Protocollo: EQol-MDS. Numero EudraCT 2010-022890-33. Cambio Principal Investigator.

Delibere

DELIBERA n. 78/2018 del 27 Febbraio 2018

“Eltrombopag for the treatment of thrombocytopenia due to low-and intermediate risk myelodyysplastic syndromes”. Protocollo: EQol-MDS. Numero EudraCT 2010-022890-33. Cambio Principal Investigator.